Welcome to the Newsroom
19 January 2015
Prima BioMed appoints Global Head of Investor Relations
SYDNEY, AUSTRALIA - Prima BioMed Ltd (ASX: PRR; NASDAQ: PBMD) (“Prima”) today announced the appointment of Stuart Roberts as Global Head of Investor Relations. Mr Roberts is an experienced investment professional, with expertise in the healthcare and biotechnology sectors, and has been involved in Australian equity research for 16 years. He builds his reputation as one of Australia’s leading sell-side biotech analysts and has been working with Baillieu Holst and Bell Potter before joining Prima. Prima CEO, Marc Voigt said the appointment followed the recent acquisition of French biotechnology company, Immutep, which has the potential to deliver significant benefits for Prima. “We now have a much more compelling investment story and Stuart is an ideal fit for our company as he has a proven track record in making complex, technology-based investment ideas easy to understand. As well he is passionate about Life Sciences and he has a deep understanding of the biotechnology sector,” Mr Voigt said.
Article as pdf